Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2023 May 5;14:1213053. doi: 10.3389/fphar.2023.1213053

Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis

Frontiers Production Office 1,*
PMCID: PMC10197925  PMID: 37214470

Due to a production error, there was a mistake in the legends for Figures 68 as published. The legend of Figure 6 matches the graph of Figure 7, the legend of Figure 7 matches the graph of Figure 8, and the legend of Figure 8 matches the graph of Figure 6. The correct legends appear below. The publisher apologizes for this mistake.

FIGURE 6.

FIGURE 6

Forest plot of efficacy represents the direct and indirect comparison.

FIGURE 8.

FIGURE 8

Forest plot of grade 3/4 adverse events of decitabine vs. conventional care regimens (direct evidence-RR).

FIGURE 7.

FIGURE 7

Forest plot of grade 3/4 adverse events of azacitidine vs. conventional care regimens (direct evidence-RR).

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES